Gastrointestinal Stromal Tumor Approved Drugs
These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Gastrointestinal Stromal Tumor.
Found 5 Approved Drugs for Gastrointestinal Stromal Tumor
Imatinib
Brand Names
Imkeldi, Gleevec
Imatinib
Brand Names
Imkeldi, Gleevec
Form: Tablet, Solution
Method of administration: Oral
FDA approval date: May 15, 2001
Classification: Kinase Inhibitor
Imatinib mesylate tablets are a kinase inhibitor indicated for the treatment of: Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.
Sutent
Generic Name
Sunitinib
Sutent
Generic Name
Sunitinib
Form: Capsule
Method of administration: Oral
FDA approval date: January 26, 2006
Classification: Kinase Inhibitor
Sunitinib malate capsules are a kinase inhibitor indicated for: treatment of adult patients with gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate.
Stivarga
Generic Name
Regorafenib
Stivarga
Generic Name
Regorafenib
Form: Tablet
Method of administration: Oral
FDA approval date: September 27, 2012
Classification: Kinase Inhibitor
STIVARGA is a kinase inhibitor indicated for the treatment of patients with: Metastatic colorectal cancer (CRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type, an anti-EGFR therapy.
Qinlock
Generic Name
Ripretinib
Qinlock
Generic Name
Ripretinib
Form: Tablet
Method of administration: Oral
FDA approval date: May 15, 2020
Classification: Kinase Inhibitor
QINLOCK is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib. QINLOCK is a kinase inhibitor indicated for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib. ( 1 )
Ayvakit
Generic Name
Avapritinib
Ayvakit
Generic Name
Avapritinib
Form: Tablet
Method of administration: Oral
FDA approval date: January 09, 2020
Classification: Kinase Inhibitor
AYVAKIT is a kinase inhibitor indicated for: Gastrointestinal Stromal Tumor (GIST) the treatment of adults with unresectable or metastatic GIST harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations.
Showing 1-5 of 5
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances